Carbapenems De-escalation as Antimicrobial Stewardship

Anti-Bacterial Agents Clinical Trial

Official title: A Cluster Randomized Controlled Trial Comparing Early and Late Carbapenems De-escalation in the Medicine Units, Maharaj Nakorn Chiang Mai Hospital

Status Completed

Clinical Trial Summary

Early de-escalation of carbapenems can reduce unnecessary use of carbaepenems compared with late de-escalation without compromised clinical outcomes

Clinical Trial Description

A cluster randomized control trial was conducted among patients receiving care at the medicine units of the Maharaj Nakorn Chiang Mai Hospital.

Patients were randomly assigned into 2 groups. The standard group followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team. The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).

Clinical outcomes included rate of de-escalation within the first 24 hour, the mortality rate, and other clinical outcomes. ;

Related Conditions & MeSH terms

• Anti-Bacterial Agents

• NCT number: NCT03114358
• Study type: Interventional
• Source: Chiang Mai University
• Status: Completed
• Phase: N/A
• Start date: June 1, 2016
• Completion date: February 28, 2017